- Home
- IVVD
IVVD
Invivyd Inc.
as 11-21-2024 4:00pm EST
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 116.8M | IPO Year: | 2021 |
| Target Price: | $7.11 | AVG Volume (30 days): | 581.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $5.20 | Next Earning Date: | 11-14-2024 |
| Revenue: | $11,564,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 72.22% |
Latest Invivyd Inc. News
IVVD Breaking Stock News: Dive into IVVD Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
7 days ago
Q3 2024 Invivyd Inc Earnings Call
GuruFocus.com
7 days ago
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
Zacks
7 days ago
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
7 days ago
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
7 days ago
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
GuruFocus.com
8 days ago
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect
GlobeNewswire
9 days ago
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
GlobeNewswire
15 days ago
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
Compare IVVD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IVVD Invivyd Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.